Artelo Biosciences, Inc. (ARTL) Investor Relations Documents

Artelo Biosciences, Inc. (ARTL) investor relations documents from the company's IR site: 2 presentations, 37 press releases; latest deck 2026-08-17. Read in-app with summaries. First-party data.

Investor Presentation - August 2026: Artelo Biosciences' August 2026 presentation details its pipeline of lipid signaling modulation therapeutics, with ART27.13 showing promise in cancer anorexia and glaucoma.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-20Press releaseArtelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART
2026-08-17Press releaseArtelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational
2026-08-17PresentationInvestor Presentation - August 2026
2026-08-13Press releaseArtelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
2026-08-10Press releaseArtelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma
2026-07-22Press releaseNew Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic E
2026-07-16Press releaseArtelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in
2026-07-14Press releaseArtelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
2026-07-13Press releaseArtelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neur
2026-07-01Press releaseArtelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associa
2026-06-30Press releaseArtelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FAB
2026-06-29Press releaseArtelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 In
2026-06-10Press releaseArtelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Assoc
2026-05-19PresentationInvestor Presentation - May 2026
2026-05-14Press releaseArtelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Resul
2026-05-14Press releasePDF
2025-12-11Proxy statementView PDF
2025-11-12Press releasePDF
2025-08-13Press releaseEarnings Release
2025-08-13Press releaseArtelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
2025-05-13Press releasePDF
2025-03-31Press releaseArtelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 20
2025-03-03Press releasePDF
2024-11-12Press releasePDF
2024-09-04Press releaseArtelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-13Press releasePDF
2024-08-13Press releaseEarnings Release
2024-05-13Press releasePDF
2024-03-25Press releasePDF
2023-11-13Press releasePDF
2023-08-10Press releasePDF
2023-08-10Press releaseEarnings Release
2023-08-10Press releaseHTML
2023-05-11Press releasePDF
2023-03-31Press releasePDF
2022-11-08Press releasePDF
2022-08-09Press releasePDF
2022-08-09Press releaseEarnings Release
2022-08-09Press releaseHTML
2022-05-12Press releasePDF

ARTL overview · ARTL earnings · ARTL financials · ARTL KPIs · ARTL ownership · ARTL peers · ARTL filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.